Prevalence and risk factors for colonization by extended-spectrum β-lactamase-producing or ST 131 Escherichia coli among asymptomatic adults in community settings in Southern Taiwan

Pin-Chieh Wu1,2,*
Jiun-Ling Wang3,4,*
Po-Ren Hsueh5
Po-Hsiang Lin6
Ming-Fang Cheng7–10
I-Fei Huang7
Yao-Shen Chen8,11
Susan Shin-Jung Lee8,11
Mar Guang-Yuan1,11
Hsien-Chung Yu1,8,11,12
Chiao-Lin Hsu1,2
Fu-Wei Wang8,13
Chi-Shen Chen1
Chih-Hsin Hung1
Wen-Chien Ko3,4

1 Department of Physical Examination Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;
2 Department of Nursing, MaHo University, Pingtung, Taiwan;
3 Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan;
4 Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan;
5 Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;
6 School of Medicine, National Yang-Ming University, Taipei, Taiwan;
7 Department of Chemical Engineering and Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan;
8 Department of Nursing, Fooyin University, Kaohsiung, Taiwan;
9 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;
10 Institute of Health Care Management, Department of Business Management, National Sun Yat-sen University, Kaohsiung, Taiwan;
11 Department of Family Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;
12 Institute of Health Care Management, National Sun Yat-sen University, Kaohsiung, Taiwan

* These authors contributed equally to this work

Correspondence: Ming-Fang Cheng
Department of Pediatrics, Kaohsiung Veterans General Hospital, No.386, Daizhong 1st Rd., Zuoying Dist., Kaohsiung City 813, Taiwan
Tel +886 346 8203
Fax +886 346 8207
Email mfcheng@vghks.gov.tw

Wen-Chien Ko
Department of Medicine, College of Medicine, National Cheng Kung University, No.138, Sheng Li Road, Tainan 704, Taiwan
Tel +886 235 3535 Ext. 5382
Fax +886 235 3535
Email winston421@yahoo.com

Purpose: Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is common in Asia, especially in China and Southeast Asia. There are no data about fecal carriage of ESBL-EC and mcr-1-positive E. coli in Taiwan, and few studies focusing on the risk factors of asymptomatic fecal carriage of epidemic ST131 E. coli have been published.

Patients and methods: From healthy inhabitants attending health examinations at a medical center in southern Taiwan in 2017, we collected 724 stool samples, which were examined for ESBL-EC fecal carriage using chromogenic medium. ST131 and mcr-1-positive E. coli were also investigated using multiplex PCR. Clinical data from all participating adults were collected to analyze the risk factors for fecal ESBL-EC or ST131 E. coli carriage.

Results: The prevalence rate of asymptomatic ESBL-EC fecal carriage in adults was 1.9% (14/724). ST131 was found in 22 (3.0%) adults and mcr-1-positive E. coli was found in three (0.4%) adults. A multivariate analysis showed that the risk factors associated with ESBL-EC carriage were diabetes mellitus (adjusted odds ratio [aOR]: 5.5, 95% confidence interval [CI]: 1.3–22.7), a history of colon polyps (aOR: 6.4, 95% CI: 1.6–24.9), and chronic renal insufficiency (aOR: 20.7, 95% CI: 1.4–305.7). Underlying cancer (aOR: 4.8, 95% CI: 1.0–22.5) and stroke (aOR: 18.0, 95% CI: 1.6–207.5) were associated with ST131 E. coli fecal carriage. In our cohort, travel to Asian countries and food habit were not associated with ST131 or ESBL-EC fecal carriage.

Conclusions: The ESBL-EC or ST131 E. coli fecal carriage rate is low among asymptomatic adults in Taiwan. Certain underlying medical conditions were associated with their fecal carriage.

Keywords: fecal colonization, extended-spectrum β-lactamase, sequence type, MCR1, Escherichia coli

Introduction

Escherichia coli is a normal inhabitant in the human gastrointestinal tract. However, it is also an important pathogen in adults. In previous decades, the occurrence of extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae, which causes treatment failure of cephalosporin therapy, has become a remarkable epidemiological event. The prevalence of ESBL-E.coli (ESBL-EC) fecal carriage in healthy adults has been increasing alarmingly, at an annual rate of 5.4%
worldwide. Recently, the prevalence of asymptomatic ESBL-EC carriage was about 5–8% in Europe, 2% in America, 6% in Japan, 19% in India, 30% in China, and 30–50% in Thailand. Antibiotic exposure within 6 months, daily animal contact, or travelling to Africa or Asia, had been linked to asymptomatic ESBL-EC fecal carriage. Colistin was considered to be the last-line antimicrobial agent for treating patients with multidrug-resistant bacteria, but in 2015, the plasmid-mediated colistin resistance gene, mcr-1, was first described in China. Since then, mcr-1 has been identified in the environment, animals, and humans. However, there are no data on fecal carriage of ESBL-EC and mcr-1 E. coli in asymptomatic people in other Asian regions including Taiwan. Moreover, few studies have focused on the risk factors for fecal carriage of ST131 E. coli, an epidemic strain, in the asymptomatic population. Therefore, the aims of this study were to determine the prevalence and risk factors for asymptomatic carriage of ESBL-EC, mcr-1 E. coli, or ST131 E. coli in Taiwan.

Materials and methods

Participants

This study was conducted from April 2016 to June 2017 at the health check center in Kaohsiung Veterans General Hospital, which is located in southern Taiwan. All individuals visiting the health check center routinely fill out a standardized questionnaire, which including demographic data, personal history, medical history, and underlying chronic illness (such as peptic ulcer or colonic polyps, antibiotic therapy, or probiotic use in the past 3 months), boiled or unboiled drinking water, and diet habits. The aforementioned data was recorded by one physician at our center during health exam interview. The participants were randomly selected and their residual fecal samples for fecal occult blood tests were collected. Only individuals whose data in the dataset of the questionnaires was intact were included in this study. Hyperuricemia was defined as a serum uric acid level ≥7 mg/dL, and chronic renal diseases were defined as serum creatinine >1.5 mg/dL. With a high prevalence of ESBL-EC in Asia, especially in Southeast Asia, India, and China, we also collected the participants’ travel information. The study was approved by the Ethics Committee at the Kaohsiung Veterans General Hospital (VGHKS16-CT2-04). The ethics committee waived the need for written informed consent provided by participants due to the noninterventional and retrospective nature of the study. Because all patient data were analyzed in anonymity, no additional informed consent was required.

Isolation of bacteria and microbiological analysis

Each stool sample was spread on a CHROMagar™ ECC plate (CHROMagar, Paris, France) and incubated at 37 °C for 24 h and up to two E. coli colonies were selected. If the colony color was dark pink to reddish, it was spread onto a CHROMagar™ ESBL plate (CHROMagar, Paris, France) to identify ESBL-EC isolates. ESBL genes, including blaCTX-M, blashV, blatEM, blaoXA-1, blatIPM, and blavIM, were assessed using the polymerase chain reaction (PCR) using previously described primers and methods if ESBL-EC fecal carriage was found using chromogenic medium. PCR amplification was performed as follows: initial denaturation at 94 °C for 10 min; 30 cycles of 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 1 min; and a final elongation step at 72 °C for 7 min. Four E. coli sequence types, including ST69, ST73, ST95, and ST131, were studied using primers and a PCR method, which were previously described, with the following cycling conditions: an initial denaturation at 94 °C for 3 min; 30 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s; and one final cycle of 72 °C for 5 min. The ESBL-EC multilocus sequence types (MLST) were confirmed by testing seven housekeeping gene sequences (adm, fumC, gyrB, idi, mdh, purA, and recA). Screening mcr-1 in E. coli isolates was conducted using PCR with the primers CLR5-F (5'-CGTCATCGCGTTCGTTTGTGC-3') and CLR5-R (5'-CCGTCGCGTTCGTTTGTGC-3') with the initial denaturation conditions of 94 °C for 15 min; 25 cycles of 94 °C for 30 s, 58 °C for 90 s, and 72 °C for 60 s; and a final cycle of 72 °C for 10 min. ST131-positive control isolates and ESBL gene-positive and mcr-1-positive isolates were obtained from previous study.

Antimicrobial susceptibility

Cefazolin, ceftriaxone, and levofloxacin antibiotic susceptibility was measured using the disk diffusion technique on Muller-Hinton medium, according to the Clinical Laboratory Standard Institute (CLSI) guidelines. Antimicrobial susceptibility of ampicillin/sulbactam, piperacillin/tazobactam, cefazolin, cefmetazole, cefotaxime, ceftazidime, cefepime, ertapenem, meropenem, imipenem, amikacin, gentamycin, ciprofloxacin, levofloxacin, trimethoprim/sulfamethoxazole, and tigecycline for the mcr-1-positive E. coli isolates was measured using the Vitek 2 system (Vitek AMS; bioMerieux).
Vitek Systems Inc., Hazelwood, MO, USA). The minimum inhibitory concentration (MIC) of colistin was determined using the broth microdilution test and interpreted based on the 2017 CLSI guidelines.17

**Statistical analysis**
Categorical variables were analyzed using the chi-square and Fisher’s exact tests and the independentsamplest-test was used to analyze continuous variables in univariate analysis. Multivariable analyses in the logistic regression model were used to study risk factors of asymptomatic ESBL-EC and ST131 *E. coli* carriage. Variables with a *P*-value of ≤0.1 in univariate analyses were entered into a forward logistical regression analysis. *P*-values <0.05 were considered to be statistically significant. The adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using SPSS version 20.0 for Windows (SPSS Inc., Armonk, NY, USA).

**Results**
During the study period, fecal occult blood tests were performed in 5,042 individuals. Among them, 743 individuals were randomly selected for enrollment and 724 participants were finally included in the study due to 19 individuals with incomplete data in the dataset of the questionnaires. There were 513 *E. coli* isolates found in the stool in the PCR study. The participants’ mean age was 46.9 years, and females predominated, accounting for 52.1% of the study population. Common underlying diseases included hypertension (101/724 individuals, 14%), diabetes mellitus (31/724, 4.3%), and cancer (17/724, 2.3%). Antibiotic therapy in the past year. Three isolates were susceptible to piperacillin/tazobactam, cefazolin, cefmetazole, cefotaxime, cephalothin, cefepime, ertapenem, meropenem, imipenem, amikacin, gentamicin, ciprofloxacin, levofloxacin, and tigecycline. The colistin MIC in three isolates was 2, 6, and 12 mg/L, respectively (Table 4). Three subjects were healthy without chronic underlying diseases, but one had traveled to China within the past year. Three isolates were susceptible to piperacillin/tazobactam, cefazolin, cefmetazole, cefotaxime, and tigecycline. The colistin MIC in three isolates was 2, 2, and 4 mg/L, respectively (Table 4).

**Discussion**
The prevalence and risk factors for ESBL-EC carriage in asymptomatic individuals have been described previously in many regions of the world.5−6 In this study, the prevalence of ESBL-EC carriage in healthy people in Taiwan was about 2%, lower than those in other areas of Asia. We found that people with a medical history of diabetes mellitus, chronic renal diseases, or colonic polyps had an
Table 1 Characteristics of 724 subjects with and without fecal extended-spectrum beta-lactamase-producing *Escherichia coli* carriage

| Variables                                      | Carriers (n=14) | Non-carriers (n=710) | Unadjusted OR (95% CI) | P-values | Adjusted OR (95% CI) | P-values |
|------------------------------------------------|----------------|---------------------|------------------------|----------|----------------------|----------|
| **Demographic**                                |                |                     |                        |          |                      |          |
| Age, mean ± standard deviations (years)        | 48.8±11.8      | 46.9±10.0           | 2.3 (0.7–7.5)          | 0.473    |                      | 0.143    |
| Male                                           | 4 (28.6%)      | 343 (48.3%)         | 0.9 (0.3–3.3)          | 1.000    |                      |          |
| **Occupation in health care setting**          |                |                     |                        |          |                      |          |
| Diet habit                                      |                |                     |                        |          |                      |          |
| Boiled water use                               | 3 (21.4%)      | 164 (23.1%)         | 0.6 (0.1–2.6)          | 0.746    |                      |          |
| Vegetarian                                     | 11 (78.6%)     | 528 (74.4%)         | 0.9 (0.3–3.3)          | 1.000    |                      |          |
| Daily animal contact                           | 1 (7.1%)       | 28 (3.9%)           | 0.5 (0.1–4.2)          | 0.439    |                      |          |
| **Travel abroad in the past 12 months**        |                |                     |                        |          |                      |          |
| Asia countries                                 | 8 (57.1%)      | 315 (44.4%)         | 1.6 (0.6–4.9)          | 0.341    |                      |          |
| Europe                                         | 1 (7.1%)       | 29 (4.1%)           | 1.8 (0.2–14.3)         | 0.450    |                      |          |
| Africa                                         | 0              | 3 (0.4%)            | 1.0 (0.0–25.0)         | 1.000    |                      |          |
| North America                                  | 1 (7.1%)       | 37 (5.2%)           | 1.4 (0.2–11.0)         | 0.533    |                      |          |
| Oceania                                        | 0              | 8 (1.1%)            | 1.0 (0.0–30.0)         | 1.000    |                      |          |
| **Medical history**                            |                |                     |                        |          |                      |          |
| Antibiotic treatment in the past 3 months      | 1 (7.1%)       | 60 (8.5%)           | 0.8 (0.1–6.5)          | 1.000    |                      |          |
| Probiotics use in the past 3 months            | 2 (14.3%)      | 170 (23.9%)         | 0.5 (0.1–24)           | 0.537    |                      |          |
| Hypertension                                   | 2 (14.3%)      | 99 (13.9%)          | 1.0 (0.2–47)           | 1.000    |                      |          |
| Hyperlipidemia                                 | 2 (14.3%)      | 71 (10.0%)          | 1.5 (0.3–6.8)          | 0.643    |                      |          |
| Diabetes mellitus                              | 3 (21.4%)      | 28 (3.9%)           | 6.6 (1.8–25.2)         | 0.019    | 5.5 (1.3–22.7)       | 0.002    |
| Stroke                                         | 0              | 3 (0.4%)            | 1.0 (0.0–30.0)         | 1.000    |                      |          |
| Gout or hyperuricemia                          | 1 (7.1%)       | 28 (3.9%)           | 1.9 (0.2–14.8)         | 0.439    |                      |          |
| Renal function impairment                      | 1 (7.1%)       | 86 (12.1%)          | 0.6 (0.1–4.3)          | 1.000    |                      |          |
| Chronic hepatitis B virus infection             | 1 (7.1%)       | 86 (12.1%)          | 27.2 (2.3–319.5)       | 0.057    | 20.7 (1.4–305.7)     | 0.028    |
| Chronic hepatitis C virus infection             | 0              | 7 (1.0%)            | 1.0 (0.0–30.0)         | 1.000    |                      |          |
| Colonic polyps                                 | 3 (21.4%)      | 31 (4.4%)           | 6.0 (1.6–22.5)         | 0.024    | 6.4 (1.6–25.0)       | 0.007    |
| Cancer                                         | 0              | 17 (2.4%)           | 1.0 (0.0–30.0)         | 1.000    |                      |          |

Abbreviations: OR, odds ratio; CI, confidence interval.
increased risk of fecal ESBL-EC carriage, in accordance with earlier studies indicating that individuals with diabetes and chronic renal diseases were more likely to have ESBL-producing Enterobacteriaceae colonization or infection.\textsuperscript{18,19} Although a recent study suggested that gut microbes may influence the development of colonic polyps,\textsuperscript{20} the relationship between colonic polyps and ESBL-EC carriage requires further confirmation. Spread of ESBL-EC in the community may be related to the transmission of ESBL-EC by food, environmental dissemination, and carriage in domestic and wild animals.\textsuperscript{21} However, in this study, fecal carriage of ESBL-EC was not associated with meat consumption, unboiled water use, occupation in the health care setting, or daily animal contact, and previous antibiotic use did not increase the risk of ESBL-EC carriage in asymptomatic people. These results were consistent with previous studies.\textsuperscript{4,6,22}

In a systemic review and meta-analysis, travelling to Asia and Africa was linked to fecal colonization with ESBL-EC,\textsuperscript{1} which cannot be confirmed in our cohort. It is not surprising because most studies showing a positive relationship between travelling and ESBL-EC carriage were conducted in Europe and North America,\textsuperscript{23} and our participants were Taiwanese who had more opportunities to meet Asians or visit other environments, which decreased the impact of travel on ESBL-EC carriage.

The ST131 \textit{E. coli} clone is an important cause of fluoroquinolone-resistant \textit{E. coli} infections,\textsuperscript{24} which is consistent with our result that levofloxacin resistance was more common in ST131 \textit{E. coli}. The emergence of ST131 in the community would pose a challenge to empirical therapy for many community-acquired infections. ST131 transmission among people was documented after household contact with ST131 carriers,\textsuperscript{25} highlighting the potential health impact of ST131 carriers. However, few studies focused on the risk factors for epidemic ST131 \textit{E. coli} carriage in the asymptomatic population. In this study, individuals with underlying cancer or stroke had a higher risk of ST131 \textit{E. coli} carriage. A previous study in Korea reported that ST131 was the most common sequence type of ESBL-EC bacteremia in cancer patients,\textsuperscript{26} suggesting an increased susceptibility to ST131 colonization in these patients. However, to the best of our knowledge, there is no evidence suggesting that people with prior stroke had an increased risk of ST131 \textit{E. coli} carriage; this warrants further confirmation. Moreover, we found that drinking boiled water tended to protect against ST131 \textit{E. coli} carriage (75% vs 59%; \(P=0.09\)). Human ST131 carriage has been relevant to the water source of ST131 isolates.\textsuperscript{27,28} However, direct evidence to verify that unboiled water is the source of ST131 \textit{E. coli} have not yet been found.

In Taiwan, \textit{mcr-1}-harboring Enterobacteriaceae isolates have been found in patients and food-producing animals.\textsuperscript{8,15,29,30} A recent study including ten cases of \textit{mcr-1}-harboring Enterobacteriaceae bacteremia revealed that 50% of them were hospitalized within 3 months before bacteremia episodes and most subjects had chronic diseases.\textsuperscript{15} Notably, all ten patients denied recent travel abroad. Characteristically, our \textit{mcr-1}-harboring \textit{E. coli} isolates were discovered from three asymptomatic adults without chronic diseases or recent exposure to antibiotics. The relevance of recent travel to China in

| Isolate number | \textit{bla}_{CTX-M} | \textit{bla}_{TEM} | \textit{bla}_{SHV} | \textit{bla}_{OXA-1} | \textit{bla}_{IMP} | \textit{bla}_{VIM} |
|----------------|---------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| No. 1          | -                   | -                 | +                 | -                 | -                 | -                 |
| No. 2          | -                   | -                 | +                 | -                 | -                 | -                 |
| No. 3          | -                   | -                 | +                 | -                 | -                 | -                 |
| No. 4          | +                   | +                 | +                 | +                 | +                 | +                 |
| No. 5          | -                   | -                 | +                 | -                 | +                 | -                 |
| No. 6          | +                   | -                 | -                 | +                 | -                 | -                 |
| No. 7          | -                   | +                 | +                 | -                 | +                 | -                 |
| No. 8          | +                   | +                 | -                 | +                 | -                 | +                 |
| No. 9          | +                   | +                 | -                 | -                 | -                 | -                 |
| No. 10         | -                   | -                 | -                 | -                 | -                 | -                 |
| No. 11         | -                   | -                 | -                 | -                 | -                 | -                 |
| No. 12         | -                   | -                 | -                 | -                 | -                 | -                 |
| No. 13         | -                   | -                 | -                 | -                 | -                 | -                 |
| No. 14         | -                   | -                 | -                 | -                 | -                 | -                 |

\textbf{Note:} "+" indicates the presence of specific gene, and "-" indicates the absence.
Table 3 Characteristics of 724 subjects with and without fecal ST131 *Escherichia coli* carriage

| Variables                                      | Carriers (n=22) | Non-carriers (n=702) | Unadjusted OR (95% CI) | P-values | Adjusted OR (95% CI) | P-values |
|------------------------------------------------|----------------|----------------------|------------------------|----------|----------------------|----------|
| **Demographic data**                           |                |                      |                        |          |                      |          |
| Age, mean ± standard deviations (years)        | 45.8±11.0      | 47.0±10.0            | 1.3 (0.6–3.2)          | 0.608    | 1.3 (0.6–3.2)        | 0.503    |
| Male                                           | 9 (40.9%)      | 338 (48.1%)          | 2.0 (0.8–4.7)          | 0.133    | 2.0 (0.8–4.7)        | 0.133    |
| Occupation in health care setting              | 8 (36.4%)      | 159 (22.7%)          |                        |          |                      |          |
| **Diet habit**                                 |                |                      |                        |          |                      |          |
| Boiled water use                               | 13 (59.1%)     | 526 (74.9%)          | 0.5 (0.2–1.2)          | 0.094    | 0.5 (0.2–1.2)        | 0.094    |
| Vegetarian                                     | 1 (4.5%)       | 28 (4.0%)            | 0.9 (0.1–6.7)          | 0.599    | 0.9 (0.1–6.7)        | 0.599    |
| Daily animal contact                           | 5 (22.7%)      | 157 (22.4%)          | 1.0 (0.4–2.8)          | 1.000    | 1.0 (0.4–2.8)        | 1.000    |
| **Travel abroad in the past 12 months**        |                |                      |                        |          |                      |          |
| Asia countries                                 | 7 (31.8%)      | 316 (45.0%)          | 0.6 (0.2–1.4)          | 0.201    | 0.6 (0.2–1.4)        | 0.201    |
| Europe                                         | 0              | 30 (4.3%)            |                        | 1.000    |                      |          |
| Africa                                         | 0              | 3 (0.4%)             |                        | 1.000    |                      |          |
| North America                                  | 1 (4.5%)       | 37 (5.3%)            | 0.9 (0.1–6.5)          | 1.000    | 0.9 (0.1–6.5)        | 1.000    |
| Oceania                                        | 0              | 8 (1.1%)             |                        | 1.000    |                      |          |
| **Medical history**                            |                |                      |                        |          |                      |          |
| Antibiotic treatment in the past 3 months      | 2 (9.1%)       | 59 (8.4%)            | 1.1 (0.2–4.8)          | 0.707    | 1.1 (0.2–4.8)        | 0.707    |
| Probiotics use in the past 3 months            | 4 (18.2%)      | 168 (23.9%)          | 0.7 (0.2–2.1)          | 0.533    | 0.7 (0.2–2.1)        | 0.533    |
| Hypertension                                   | 3 (13.6%)      | 98 (14.0%)           | 1.0 (0.3–3.4)          | 1.000    | 1.0 (0.3–3.4)        | 1.000    |
| Hyperlipidemia                                 | 4 (18.2%)      | 69 (9.8%)            | 2.0 (0.7–6.2)          | 0.266    | 2.0 (0.7–6.2)        | 0.266    |
| Diabetes mellitus                              | 1 (4.5%)       | 30 (4.3%)            | 1.1 (0.1–8.2)          | 1.000    | 1.1 (0.1–8.2)        | 1.000    |
| Stroke                                         | 1 (4.5%)       | 2 (0.3%)             | 16.7 (1.5–191.1)       | 0.089    | 16.7 (1.5–191.1)     | 0.089    |
| Gout or hyperuricemia                          | 2 (9.1%)       | 27 (3.9%)            | 2.5 (0.6–11.2)         | 0.219    | 2.5 (0.6–11.2)       | 0.219    |
| Renal function impairment                      | 0              | 3 (0.4%)             |                        | 1.000    |                      |          |
| Chronic hepatitis B virus infection            | 1 (4.5%)       | 42 (6.0%)            | 0.3 (0.0–2.6)          | 0.501    | 0.3 (0.0–2.6)        | 0.501    |
| Chronic hepatitis C virus infection            | 0              | 7 (1.0%)             |                        | 1.000    |                      |          |
| Colonic polyps                                 | 1 (4.5%)       | 33 (4.7%)            | 0.5 (0.1–3.7)          | 1.000    | 0.5 (0.1–3.7)        | 1.000    |
| Cancer                                         | 2 (9.1%)       | 15 (2.1%)            | 4.6 (1.0–21.4)         | 0.091    | 4.6 (1.0–21.4)       | 0.091    |

Abbreviations: OR, odds ratio; CI, confidence interval.
There are some limitations to this study. First, the participants only involved urban adults who received health examinations in one city, and the representativeness of the study cohort for the Taiwan population is limited. Second, the number of patients with ESBL-EC and ST131 E. coli carriage was too small to detect certain risk factors. Last, the association of colonic polyps and ESBL-EC may be biased because of recall bias for the diagnosis of colonic polyps. A prospective study enrolling individuals with colonic polyps that were diagnosed by colonoscopy and microbiological screening of fecal ESBL-EC carriage is warranted.

**Conclusion**

Asymptomatic adults in Taiwan had a low prevalence rate of fecal ESBL-EC or ST131 E. coli carriage, which was associated with the presence of underlying medical conditions. However, only a small number of ESBL-EC and ST131 E. coli isolates were noted in the study, and the associated risk factors require further investigation.

**Ethics approval and informed consent**

The study was approved by the Ethics Committee at the Kaohsiung Veterans General Hospital (VGHKS16-CT2-04). This study was conducted in accordance with the Declaration of Helsinki. The Ethics committee waived the need for written informed consent provided by participants due to the noninterventional and retrospective nature of the study. Because all patient data were analyzed in anonymity, no additional informed consent was required.

**Acknowledgments**

We are grateful to the members of Dr. Chih-Hsin Hung’s laboratory at the I-Shou University, especially Miss Wan-Yu Hung, for their excellent work in completing the E. coli isolation and PCR. This work was supported by research grants from the Taiwan Ministry of Science and Technology, MOST 104-2314-B-075B-003-MY3, 106-2314-B-006-081-MY2, 107-2314-B-075B-004, and VGHKS107-039, 108-128

**Author contributions**

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Disclosure

The authors declare that there are no competing interests regarding the publication of this paper.

References

1. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(3):310–318. doi:10.1093/cid/ciw283
2. Luvsansharav UO, Hirai I, Niki M, et al. Prevalence of fecal carriage of extended-spectrum-beta-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother. 2011;17(5):722–725. doi:10.1007/s10156-011-0225-2
3. Luvsansharav UO, Hirai I, Niki M, et al. Analysis of risk factors for a high prevalence of extended-spectrum (beta) lactamase-producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. J Med Microbiol. 2011;60(Pt 5):619–624. doi:10.1099/jmm.0.026955-0
4. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, et al. 10-fold increase (2006–11) in the rate of healthy subjects with extended-spectrum beta-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother. 2013;68(3):562–568. doi:10.1093/jac/dks429
5. Ni Q, Tian Y, Zhang L, et al. Prevalence and quinolone resistance of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli in 6 communities and 2 physical examination center populations in Shanghai, China. Diagn Microbiol Infect Dis. 2016;84(4):428–433. doi:10.1016/j.diagmicrobio.2016.07.010
6. Ny S, Lofmark S, Borjesson S, et al. Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother. 2017;72(2):582–588. doi:10.1093/jac/dkw419
7. Liu -Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
8. Lai CC, Chuang YC, Chen CC, Tang HJ. Coexistence of MCR-1 and NDM-9 in a clinical carbapenem-resistant Escherichia coli isolate. Int J Antimicrob Agents. 2017;49(4):517–518.
9. Krishnan E, Akhras KS, Sharma H, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM. 2013;106(8):721–729.
10. Chia JH, Chu C, Su LH, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamas of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan. J Clin Microbiol. 2005;43(9):4486–4491. doi:10.1128/JCM.43.9.4486-4491.2005
11. Sidjabat HE, Paterson DL, Adams-Haschuk JM, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother. 2009;53(11):4733–4739. doi:10.1128/AAC.00533-09
12. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamas in Enterobacteriaceae. J Antimicrob Chemother. 2010;65(3):490–495. doi:10.1093/jac/dkp498
13. Belmar Campos C, Fenner I, Wiese N, et al. Prevalence and genotypes of extended spectrum beta-lactamas in Enterobacteriaceae isolated from human stool and chicken meat in Hamburg, Germany. Int J Med Microbiol. 2014;304(5-6):678–684. doi:10.1016/j.ijmm.2014.04.012
14. Doumith M, Day M, Ciesielczuk H, et al. Rapid identification of major Escherichia coli sequence types causing urinary tract and bloodstream infections. J Clin Microbiol. 2015;53(1):160–166. doi:10.1128/JCM.02562-14
15. Lai CC, Lin YT, Lin YT, et al. Clinical characteristics of patients with bacteremia due to the emergence of mer-l-harbouring Enterobacteriaceae in humans and pigs in Taiwan. Int J Antimicrob Agents. 2018;52(5):651–657. doi:10.1016/j.ijantimicag.2018.08.015
16. Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2012;56(2):618–622. doi:10.1128/AAC.00575-11
17. Jean B, Mpw P, Eliopoulos GM, Jenkins SG. M100 Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2017.
18. D BP S, Griemelprez A, de Saint-Hubert M, et al. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital. BMC Infect Dis. 2011 Jan 12;11:12. doi:10.1186/1471-2334-11-12
19. Johnson JR, Thuras P, Johnston BD, et al. The pandemic H30 subclone of Escherichia coli sequence type 131 is associated with persistent infections and adverse outcomes independent from its multidrug resistance and associations with compromised hosts. Clin Infect Dis. 2016;62(12):1529–1536. doi:10.1093/cid/ciw193
20. Peters BA, Dominiani C, Shapiro JA, et al. The gut microbiota in convalescent and septic precursors of colorectal cancer. Microbiome. 2016;4(1):69. doi:10.1186/s40168-016-0218-6
21. Oteo J, Pérez-Vázquez M, Extended-Spectrum Cβ-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23(4):320–326.
22. PL AC W, Jacquier H, Clermont O, et al. Characterization of fecal extended-spectrum-beta-lactamase-producing Escherichia coli in a remote community during a long time period. Antimicrob Agents Chemother. 2013;57(10):5060–5066. doi:10.1128/AAC.00848-13
23. Woerther PL, Andremont A, Kantele A. Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. J Travel Med. 2017;24(suppl 1):S29–S34. doi:10.1093/jtm/taw101
24. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51(3):286–294. doi:10.1086/653932
25. Torres E, Lopez-Cerero L, Morales I, Navarro MD, Rodriguez-Bano J, Pascual A. Prevalence and transmission dynamics of Escherichia coli ST131 among contacts of infected community and hospitalized patients. Clin Microbiol Infect. 2018;24(6):618–623. doi:10.1016/j.cmi.2017.09.007
26. Ha YE, Kang CI, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42(5):403–409. doi:10.1016/j.ijantimicag.2013.07.018
27. Johnson JR, Nicolas-Chanoine MH, DebRoy C, et al. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967–2009. Emerg Infect Dis. 2012;18(4):598–607. doi:10.3201/eid1804.111627
28. M MA C-L, López C, Mamani R, et al. Detection of quinolone-resistant Escherichia coli isolates belonging to clonal groups O25b: H4-B2-ST131and O25b: H4-D-ST69in raw sewage and river water in Barcelona, Spain. J Antimicrob Chemother. 2013;68(4):758–765. doi:10.1093/jac/dks477
29. SC HW K, Wang HY, Shiau YR, Cheng MF, Lauderdale TL. Colistin resistance gene mer-l in Escherichia coli isolates from humans and retail meats, Taiwan. J Antimicrob Chemother. 2016;71(8):2327–2329. doi:10.1093/jac/dkw122
30. CS CY C, Wang YW, Liu YY, et al. Dissemination of mcr-1-carrying plasmids among colistin-resistant salmonella strains from humans and food-producing animals in Taiwan. *Antimicrob Agents Chemother*. 2017;61:7.

31. Pham Thanh D, Thanh Tuyen H, Nguyen Thi Nguyen T, et al. Inducible colistin resistance via a disrupted plasmid-borne mcr-1 gene in a 2008 Vietnamese *Shigella sonnei* isolate. *J Antimicrob Chemother*. 2016;71(8):2314–2317. doi:10.1093/jac/dkw173

32. Terveer EM, Nijhuis RHT, Crobach MJT, et al. Prevalence of colistin resistance gene (mcr-1) containing Enterobacteriaceae in feces of patients attending a tertiary care hospital and detection of a mcr-1 containing, colistin susceptible *E. coli*. *PLoS One*. 2017;12(6):e0178598. doi:10.1371/journal.pone.0178598

33. Bi Z, Berglund B, Sun Q, et al. Prevalence of the mcr-1 colistin resistance gene in extended-spectrum beta-lactamase-producing *Escherichia coli* from human faecal samples collected in 2012 in rural villages in Shandong Province, China. *Int J Antimicrob Agents*. 2017;49(4):493–497. doi:10.1016/j.ijantimicag.2016.12.018

34. Chan WS, Au CH, Ho DN, Chan TL, Ma ES, Tang BS. Prospective study on human fecal carriage of Enterobacteriaceae possessing mcr-1 and mcr-2 genes in a regional hospital in Hong Kong. *BMC Infect Dis*. 2018;18(1):81. doi:10.1186/s12879-018-3109-6